Teleflex (NYSE:TFX) Upgraded at Bank of America

Bank of America upgraded shares of Teleflex (NYSE:TFX) from a neutral rating to a buy rating in a report issued on Monday morning, MarketBeat Ratings reports. The brokerage currently has $158.00 target price on the medical technology company’s stock, up from their previous target price of $145.00.

Several other analysts also recently commented on TFX. BMO Capital Markets assumed coverage on shares of Teleflex in a report on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price objective on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research report on Monday, September 21st. Needham & Company LLC upped their price target on shares of Teleflex from $159.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Mizuho raised their price objective on Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, Zacks Research upgraded Teleflex from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Teleflex has an average rating of “Moderate Buy” and a consensus target price of $155.20.

Teleflex Price Performance

TFX opened at $124.95 on Monday. The business’s 50-day moving average is $133.49 and its two-hundred day moving average is $128.98. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.60 and a quick ratio of 2.12. Teleflex has a 1 year low of $100.18 and a 1 year high of $145.00. The firm has a market capitalization of $5.29 billion, a PE ratio of -5.37, a price-to-earnings-growth ratio of 0.84 and a beta of 0.82.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The firm had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. During the same quarter in the prior year, the company posted $3.73 earnings per share. The company’s revenue for the quarter was up 28.9% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Research analysts anticipate that Teleflex will post 7.26 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Friday, August 14th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend was Friday, August 14th. Teleflex’s dividend payout ratio is presently -5.84%.

Hedge Funds Weigh In On Teleflex

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. acquired a new position in shares of Teleflex in the second quarter worth $226,000. WINTON GROUP Ltd acquired a new stake in Teleflex in the second quarter valued at approximately $276,000. Engineers Gate Manager LP purchased a new position in Teleflex in the second quarter worth approximately $304,000. Integrated Wealth Concepts LLC purchased a new position in Teleflex in the second quarter worth approximately $57,000. Finally, Allworth Financial LP grew its holdings in Teleflex by 91.8% during the 2nd quarter. Allworth Financial LP now owns 349 shares of the medical technology company’s stock worth $44,000 after acquiring an additional 167 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, physicians and other healthcare providers. Its products are designed to support minimally invasive procedures, critical care and a range of clinical applications.

The company’s portfolio includes devices for vascular access and intervention, anesthesia, respiratory care, emergency medicine, surgery, urology and pain management. Teleflex markets products under brands including Arrow, which is known for vascular access and catheter-based technologies, as well as other specialized product lines used in hospitals and outpatient settings.

Teleflex serves healthcare markets in North America, Europe, Asia and other international regions.